Inflammatix
PrivateLast Round
Series E
Sep 12, 2024
Total Funding Raised
$209.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Inflammatix is a molecular diagnostics company that develops rapid tests to measure immune responses and assist healthcare providers in diagnosing acute infections and sepsis using advanced machine-learning algorithms.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Government Contracts, Hardware Sales, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Inflammatix Comparables
Compare Inflammatix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MeMed | 87% | |
| Cytovale | 86% | |
| Immunexpress | 79% |
Inflammatix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Sep 12, 2024 | ||||
| Grant | Nov 18, 2021 | ||||
| Series D | Mar 16, 2021 | ||||
| Series C | Jan 10, 2020 | ||||
| Grant | Nov 14, 2019 |
Key People
Founding team and executive leadership
Inflammatix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Think.Health | Series C, Series E, Series D |
| Grey Sky Venture Partners | Series C |
| Administration for Strategic Preparedness and Response | Grant |
| Khosla Ventures | Series D, Series C, Series E |
| Iberis Capital | Series E |
| OSF Ventures | Series D, Series E |
| Northpond Ventures | Series D, Series C, Series E |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 67% MoM, from 3.1K to 5.2K.
- Apr 26, 2026
Added Vhss1, a veterinary services startup, as a customer.
Inflammatix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Inflammatix's valuation, stock price, and market status.
Is Inflammatix a public or private company?
Inflammatix is a private company.
What is the current stock price of Inflammatix?
Inflammatix is a private company, so its shares have no public market price. Caplight tracks Inflammatix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Inflammatix worth (valuation)?
Valuation information for Inflammatix is not publicly available.
Can I buy Inflammatix stock?
Inflammatix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Inflammatix's last funding round?
Inflammatix's most recent funding round was Series E on September 12, 2024.
Who are the main investors in Inflammatix?
Key investors in Inflammatix include Think.Health, Grey Sky Venture Partners, Khosla Ventures, D1 Capital Partners.
Will Inflammatix IPO soon?
No public IPO plans have been announced for Inflammatix.
How can I track Inflammatix secondary market activity?
Caplight tracks bids, offers, and trades in Inflammatix's shares on secondary markets.